Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1

Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1

Current antifibrinolytic agents reduce blood loss by inhibiting plasmin active sites (e.g., aprotinin) or by preventing plasminogen/tissue plasminogen activator (tPA) binding to fibrin clots (e.g., ε-aminocaproic acid and tranexamic acid); however, they have adverse side effects. Here, we expressed...

Full description

Bibliographic Details
Main Authors: Kanagasabai Vadivel, Anne K. Zaiss, Yogesh Kumar, Frank M. Fabian, Ayman E. A. Ismail, Mark A. Arbing, Wallace G. Buchholz, William H. Velander, S. Paul Bajaj
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Journal of Clinical Medicine
Subjects:
aprotinin
ε-aminocaproic acid
tranexamic acid
antifibrinolytics
thromboelastography
Online Access:https://www.mdpi.com/2077-0383/9/11/3684

Internet

https://www.mdpi.com/2077-0383/9/11/3684

Similar Items